Literature DB >> 18323858

Role of a functional human gene polymorphism in stress responsivity and addictions.

M J Kreek1.   

Abstract

Over the past decade, enormous progress has been made in both the technical approaches and the scientific information available for studying the human genome. Therefore, increasingly, scientists have begun to address not just single-gene disorders but complex disorders. The limiting factor in most of such studies remains appropriate, well-focused detailed phenotyping of the complex disorders under study, with careful ascertainment of subjects with the specific disorder, as well as healthy control subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18323858      PMCID: PMC3810147          DOI: 10.1038/clpt.2008.5

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

1.  Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden.

Authors:  G Bart; M Heilig; K S LaForge; L Pollak; S M Leal; J Ott; M J Kreek
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

2.  Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.

Authors:  M J Kreek; J Schluger; L Borg; M Gunduz; A Ho
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

Review 3.  Drug dependence: stress and dysregulation of brain reward pathways.

Authors:  M J Kreek; G F Koob
Journal:  Drug Alcohol Depend       Date:  1998 Jun-Jul       Impact factor: 4.492

4.  Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction.

Authors:  Vadim Yuferov; David Fussell; K Steven LaForge; David A Nielsen; Derek Gordon; Ann Ho; Suzanne M Leal; Jurg Ott; Mary Jeanne Kreek
Journal:  Pharmacogenetics       Date:  2004-12

5.  Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden.

Authors:  Gavin Bart; Mary Jeanne Kreek; Jurg Ott; K Steven LaForge; Dmitri Proudnikov; Lotta Pollak; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2005-02       Impact factor: 7.853

6.  Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects.

Authors:  Gavin Bart; Lisa Borg; James H Schluger; Mark Green; Ann Ho; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2003-05-02       Impact factor: 4.030

7.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.

Authors:  J H Schluger; A Ho; L Borg; M Porter; S Maniar; M Gunduz; G Perret; A King; M J Kreek
Journal:  Alcohol Clin Exp Res       Date:  1998-10       Impact factor: 3.455

Review 9.  Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA.

Authors:  Mary Jeanne Kreek; Stefan D Schlussman; Gavin Bart; K Steven Laforge; Eduardo R Butelman
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

10.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

Authors:  David W Oslin; Wade Berrettini; Henry R Kranzler; Helen Pettinati; Joel Gelernter; Joseph R Volpicelli; Charles P O'Brien
Journal:  Neuropsychopharmacology       Date:  2003-06-18       Impact factor: 7.853

View more
  17 in total

1.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

Review 2.  The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence.

Authors:  Michael J Glass
Journal:  Vitam Horm       Date:  2010       Impact factor: 3.421

Review 3.  Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment.

Authors:  Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2011-08       Impact factor: 5.691

4.  Functions of arginine vasopressin and its receptors: importance of human molecular genetics studies in bidirectional translational research.

Authors:  Mary Jeanne Kreek; Yan Zhou; Orna Levran
Journal:  Biol Psychiatry       Date:  2011-09-15       Impact factor: 13.382

5.  Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors.

Authors:  Katharine M Seip-Cammack; Brian Reed; Yong Zhang; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2012-07-25       Impact factor: 4.530

Review 6.  Genetics of opiate addiction.

Authors:  Brian Reed; Eduardo R Butelman; Vadim Yuferov; Matthew Randesi; Mary Jeanne Kreek
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 7.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Authors:  Mary Jeanne Kreek; Orna Levran; Brian Reed; Stefan D Schlussman; Yan Zhou; Eduardo R Butelman
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  Overview and historical perspective of four papers presented on research related to the endogenous opioid system.

Authors:  Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2010-04-18       Impact factor: 4.492

Review 9.  Breaking barriers in the genomics and pharmacogenetics of drug addiction.

Authors:  M K Ho; D Goldman; A Heinz; J Kaprio; M J Kreek; M D Li; M R Munafò; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2010-10-27       Impact factor: 6.875

10.  Dysregulation of diurnal cortisol secretion affects abstinence induction during a lead-in period of a clinical trial for depressed cocaine-dependent patients.

Authors:  Wilfrid Noel Raby; Lisa Sanfilippo; Martina Pavlicova; Kenneth M Carpenter; Andrew Glass; Chukwudi Onyemekwu; Eric Roginek; Edward V Nunes
Journal:  Am J Addict       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.